Enable JavaScript to visit this website.

ATTR-CM Landing Page

2018 US ASPIRE Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Competitive Research Grant Awards for Established Investigators

Mission

The mission of the US ASPIRE ATTR cardiomyopathy program is to support specific research in science and broad clinical research through a competitive grants program that advances medical knowledge in the understanding, diagnosis and treatment of ATTR cardiomyopathy. In-scope research submissions are those that focus on ATTR cardiomyopathy, including wild-type and hereditary forms.

Background

Although recent developments have been made in the diagnosis and treatment of ATTR cardiomyopathy, more research is needed. The goal of the 2018 US ASPIRE ATTR cardiomyopathy program is to further improve our understanding of the epidemiology, science and early diagnosis and treatment of ATTR cardiomyopathy.

Request for Proposals

Pfizer invites investigators with terminal degree (MD and/or PhD and/or PharmD or equivalent) who have an established research career in ATTR Amyloidosis. Applicants should be at the associate level, professor level, or practicing clinicians who are advanced in their research careers in ATTR cardiomyopathy for greater than 5 years. Established researchers are encouraged to submit innovative research proposals designed to enhance our ability to understand the epidemiology, science and early diagnosis and treatment of patients with ATTR cardiomyopathy.

Scope of Research Areas

Epidemiology, Science and Tools for Early Diagnosis and Treatment of Patients with ATTR Cardiomyopathy.

Research Requirements

Pfizer is interested in supporting research proposals that advance our understanding of the epidemiology, science and early diagnosis and treatment of ATTR cardiomyopathy through research focused in the following areas:

  • Epidemiologic evaluations for ATTR cardiomyopathy
  • Approaches for the early diagnosis of patients including, but not limited to:
    • Multidisciplinary approaches
    • New diagnostic algorithms
    • Imaging studies
    • Non-invasive diagnostic techniques
    • Risk factors for disease penetrance
    • Markers of disease progression and natural history studies

  • Mechanistic studies to advance the basic science of amyloid formation and deposition

Research Expectations

Within the specified areas of research interest, investigators are expected to:

  • Generate data to better understand important diagnostic and clinical management issues relevant to diagnosing and treating patients with ATTR cardiomyopathy.
  • Proposals may include post-hoc exploratory analyses and well-designed retrospective or prospective analyses to generate and/or test hypotheses or studies to validate new assessments.  Be able to complete the research within 24 months of start date.
  • Present and/or publish the results of the study.


Evaluations may include standardized assessments as well as surrogate markers that may define or predict clinical response and to identify novel diagnostic strategies. See website FAQ’s for additional guidance on topics that fall outside the scope of this program.

Available Awards

This program is exclusively open to established investigators from within the US who have a terminal degree (MD and/or PhD and/or PharmD or equivalent) and have an established research career in ATTR Amyloidosis. Applicants should be at the associate level, professor level, or practicing clinicians who are advanced in their research careers in ATTR cardiomyopathy for greater than 5 years. See FAQ’s on our website for additional details. Pfizer is funding research awards ranging from $75,000 USD to a maximum of $100,000 USD each. Budgets for the program must be submitted in USD and all grants will be paid in USD. Pfizer anticipates awarding up to 3 grants for the 2018 program. Award amounts include direct costs, institutional overhead costs capped at 28% per Pfizer policy, and indirect costs. Pfizer does not pay overhead on indirect costs. Study budgets will be evaluated by the external panel and if selected for award, will be reviewed for fair market value in accordance with local policies and procedures as part of the contracting process to ensure the requested funding is commensurate with the work proposed. Project duration should be no longer than 24 months.